Kathryn Tyler Maples, PharmD, BCOP, on Elranatamab for Patients With Relapsed or Refractory Multiple Myeloma

Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses findings from the MagnetisMM-1 trial on elranatamab, a humanized bispecific molecule that targets BCMA expressed in multiple myeloma and engages CD3 on T cells. The results, of interest to advanced practitioners, support continued development of elranatamab as a single agent and in combination with standard treatments for patients with relapsed or refractory multiple myeloma (Abstract 895).